Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2021) Vol. 139, Iss. 10, pp. 1588-1592
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 110
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Robert Stuver, Gunjan L. Shah, Neha Korde, et al.
Cancer Cell (2022) Vol. 40, Iss. 6, pp. 590-591
Open Access | Times Cited: 86
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2022) Vol. 140, Iss. 26, pp. 2773-2787
Open Access | Times Cited: 73
Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
James A. Davis, Katelynn Granger, Kiera Roubal, et al.
Blood (2022) Vol. 141, Iss. 2, pp. 200-203
Open Access | Times Cited: 52
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Francesco Marchesi, Jon Salmanton‐García, Ziad Emarah, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 22-33
Open Access | Times Cited: 39
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
Jon Salmanton‐García, Francesco Marchesi, María Gomes da Silva, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101939-101939
Open Access | Times Cited: 27
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102553-102553
Open Access | Times Cited: 12
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Helen Parry, Graham McIlroy, Rachel Bruton, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 33
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Jon Salmanton‐García, Francesco Marchesi, Andreas Glenthøj, et al.
HemaSphere (2022) Vol. 6, Iss. 11, pp. e789-e789
Open Access | Times Cited: 33
Impact of COVID-19 in patients with multiple myeloma based on a global data network
Joaquín Martínez‐López, Gema Hernández, R. Alonso, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 12
Open Access | Times Cited: 39
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Arielle Elkrief, Julie Wu, Chinmay Jani, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 303-330
Open Access | Times Cited: 35
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era
Jérémie Zerbit, Marion Detroit, Antoine Meyer, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2377-2377
Open Access | Times Cited: 23
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 6, pp. 481-489
Open Access | Times Cited: 21
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Giuseppe Rossi, Jon Salmanton‐García, Chiara Cattaneo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 98-110
Open Access | Times Cited: 11
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Tobias Lahmer, Jon Salmanton‐García, Francesco Marchesi, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 1125-1141
Open Access | Times Cited: 4
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Heng Joo Ng, Maaz Kamal Alata, Quang The Nguyen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 3-15
Open Access | Times Cited: 19
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant
Sam M. Murray, Maria Chiara Barbanti, Cori Campbell, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 4, pp. 668-679
Open Access | Times Cited: 18
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemic
Chiara Cattaneo, Lorenzo Masina, Chiara Pagani, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 205-207
Open Access | Times Cited: 18
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
Fabian Ullrich, Christine Hanoun, Amin T. Turki, et al.
European Journal Of Haematology (2022) Vol. 109, Iss. 4, pp. 364-372
Open Access | Times Cited: 17
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 17
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
Jon Salmanton‐García, Francesco Marchesi, Philipp Koehler, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 4, pp. 106952-106952
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top